|First Author, Year (Ref. #)||Experimental AMI Model||Cardioprotective Agents or Interventions||Cardioprotective Effect||Signaling Pathways|
|Rastaldo et al., 2012 (48)||Isolated rat heart||Hybrid molecule containing NO donor and antioxidant||Additive effects on reducing MI size||Mitochondrial KATP channel|
|Lougiakis et al., 2016 (47)||In vivo rabbit||Hybrid molecule containing H2S-donor and adenosine analogue at reperfusion||Additive effects on reducing MI size||cGMP/PKG/phospholamban pathway|
|García-Ruiz et al., 2016 (17) and Garcia-Prieto et al., 2017 (27)||In vivo pig|
In vivo mouse
|Intravenous metoprolol targeting simultaneously cardiomyocytes (reducing energy demand), and neutrophils (inhibiting migration and neutrophil–platelet coaggregates)||Reduces infarct size when given at different times of ischemia duration, but effect is stronger when given earlier||Cardiomyocyte oxygen consumption reduction and neutrophil conformational re-arrangements|
cGMP = cyclic guanosine monophosphate; PKG = protein kinase G; other abbreviations as in Table 1.
↵∗ Other criteria are as per Table 1.